Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC

(RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Ultragenyx Pharmaceutical : appoints Dr. Wladimir Hogenhuis as COO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/19/2018 | 07:07am EST

Ultragenyx Pharmaceutical (NASDAQ:RARE) has expanded its leadership team with the appointment of Wladimir (Vlad) Hogenhuis, M.D., as Chief Operating Officer (COO), effective September 28. Dr. Hogenhuis will report to Emil D. Kakkis, Chief Executive Officer, and will serve on the Executive Leadership Team.

Dr. Hogenhuis joins Ultragenyx from GlaxoSmithKline, where he most recently served as Senior VP and General Manager, Specialty Franchise.

(c) NNA 2018 LEBANON Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE -0.12% 1536.2 Delayed Quote.3.14%
ULTRAGENYX PHARMACEUTICAL INC 2.68% 59.82 Delayed Quote.37.58%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ULTRAGENYX PHARMACEUTICAL
02/22ULTRAGENYX PHARMACEUTICAL : Announces Positive 24-week Data from First Cohort of..
AQ
02/21ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits..
AQ
02/21ULTRAGENYX PHARMACEUTICAL : Announces Positive 24-week Data from First Cohort of..
AQ
02/20ULTRAGENYX PHARMACEUTICAL : Management's Discussion and Analysis of Financial Co..
AQ
02/19ULTRAGENYX : 4Q Earnings Snapshot
AQ
02/19ULTRAGENYX PHARMACEUTICAL INC. : Results of Operations and Financial Condition, ..
AQ
02/19Ultragenyx Reports Fourth Quarter and Full Year 2018 Financial Results and Co..
GL
02/16Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita (bu..
AQ
02/15Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita fro..
AQ
02/14ULTRAGENYX PHARMACEUTICAL : and Kyowa Kirin Announce Positive 64-Week Results fo..
AQ
More news
Financials ($)
Sales 2019 101 M
EBIT 2019 -359 M
Net income 2019 -345 M
Finance 2019 163 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 28,6x
EV / Sales 2020 13,4x
Capitalization 3 068 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 72,8 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC37.58%3 068
GILEAD SCIENCES4.80%85 043
VERTEX PHARMACEUTICALS13.49%47 491
REGENERON PHARMACEUTICALS13.51%45 364
GENMAB0.14%9 991
SAREPTA THERAPEUTICS INC28.27%9 870